JPH0517347A - Vitamin k-solubilizing agent - Google Patents
Vitamin k-solubilizing agentInfo
- Publication number
- JPH0517347A JPH0517347A JP19251091A JP19251091A JPH0517347A JP H0517347 A JPH0517347 A JP H0517347A JP 19251091 A JP19251091 A JP 19251091A JP 19251091 A JP19251091 A JP 19251091A JP H0517347 A JPH0517347 A JP H0517347A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- solubilizing agent
- fatty acid
- monoester
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002904 solvent Substances 0.000 title claims abstract description 13
- 229940088594 vitamin Drugs 0.000 title abstract description 6
- 229930003231 vitamin Natural products 0.000 title abstract description 6
- 235000013343 vitamin Nutrition 0.000 title abstract description 6
- 239000011782 vitamin Substances 0.000 title abstract description 6
- 150000003722 vitamin derivatives Chemical class 0.000 title abstract description 6
- 229930006000 Sucrose Natural products 0.000 claims abstract description 12
- 239000005720 sucrose Substances 0.000 claims abstract description 12
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- -1 sucrose fatty acid ester Chemical class 0.000 claims description 21
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 15
- 229930195729 fatty acid Natural products 0.000 claims description 15
- 239000011712 vitamin K Substances 0.000 claims description 12
- 235000019168 vitamin K Nutrition 0.000 claims description 12
- 229930003448 Vitamin K Natural products 0.000 claims description 11
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 11
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 11
- 229940046010 vitamin k Drugs 0.000 claims description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 2
- 239000002244 precipitate Substances 0.000 abstract description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 230000003381 solubilizing effect Effects 0.000 description 9
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 229940035023 sucrose monostearate Drugs 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 239000004359 castor oil Substances 0.000 description 6
- 235000019438 castor oil Nutrition 0.000 description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000011772 phylloquinone Substances 0.000 description 4
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、ビタミンＫの可溶化剤
及びそれを含有したビタミンＫの安定な可溶化水溶液に
関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a solubilizing agent for vitamin K and a stable solubilizing aqueous solution of vitamin K containing the same.
【０００２】[0002]
【従来の技術】ビタミンＫ類，特にビタミンＫ1 ，Ｋ2
は血液の凝固を促進させる作用を持つ脂溶性ビタミンで
ある。このビタミンＫを注射液として用いる場合、ポリ
オキシエチレン硬化ヒマシ油やポリオキシエチレンソル
ビタン脂肪酸エステル等の非イオン界面活性剤やプロピ
レングリコール，ポリエチレングリコール，ベンジルア
ルコール，トリグリセリド等の可溶化助剤を用いて水に
可溶化させて使用している。2. Description of the Related Art Vitamin Ks, especially vitamins K 1 and K 2
Is a fat-soluble vitamin that promotes blood coagulation. When using this vitamin K as an injectable solution, a nonionic surfactant such as polyoxyethylene hydrogenated castor oil or polyoxyethylene sorbitan fatty acid ester or a solubilizing aid such as propylene glycol, polyethylene glycol, benzyl alcohol or triglyceride is used. It is solubilized in water before use.
【０００３】[0003]
【発明が解決しようとする課題】しかしながら、このよ
うな従来のビタミンＫの可溶化技術にあっては、通常非
イオン性界面活性剤として用いられるポリオキシエチレ
ンソルビタン脂肪酸エステル（例えばポリソルベート８
０）は、可溶化能力があまり高くなく、また、ポリオキ
シエチレン硬化ヒマシ油は水に溶けにくい欠点がある。
そして、これらの非イオン界面活性剤を用いて可溶化溶
液を製造した場合、経時的に沈殿が析出したり白濁が生
じ不安定であった。このため、プロピレングリコールや
ポリエチレンオキサイド，油脂等の助剤を併用し、安定
化させる方法も提案されているが、沈殿の析出防止や白
濁の防止に関して満足できるものではなく、また注射液
の安全性の立場からは主剤以外の添加剤を多用すること
は好ましくない。However, in such a conventional vitamin K solubilization technique, a polyoxyethylene sorbitan fatty acid ester (for example, polysorbate 8) usually used as a nonionic surfactant is used.
0) has a drawback that the solubilizing ability is not so high, and that polyoxyethylene hydrogenated castor oil is difficult to dissolve in water.
When a solubilizing solution was produced using these nonionic surfactants, it was unstable due to precipitation or clouding over time. Therefore, a method of stabilizing by using an auxiliary agent such as propylene glycol, polyethylene oxide, fats and oils has also been proposed, but it is not satisfactory in terms of preventing precipitation of precipitates and preventing cloudiness, and the safety of the injection solution is high. From the standpoint of, it is not preferable to use many additives other than the main agent.
【０００４】[0004]
【課題を解決するための手段】本発明はこのような従来
の問題点に着目してなされたもので、鋭意研究の結果、
ビタミンＫの可溶化力、水溶性に優れ、かつ経時的沈殿
や白濁の生じない安定な可溶化剤を見いだしたのであ
る。すなわち、モノエステル含有率が９０重量％以上の
ショ糖脂肪酸エステルを含有するビタミンＫ可溶化剤で
ある。The present invention has been made by paying attention to such conventional problems, and as a result of earnest research,
They have found a stable solubilizing agent that is excellent in solubilizing ability of vitamin K and water solubility and does not cause precipitation or clouding with time. That is, it is a vitamin K solubilizer containing a sucrose fatty acid ester having a monoester content of 90% by weight or more.
【０００５】本発明に使用するショ糖脂肪酸エステルの
モノエステルとは、ショ糖と高級脂肪酸のエステル化合
物であり、そのエステル化度が１のものを指す。モノエ
ステル含有率は９０％以上であり、ジエステル以上のエ
ステル含有率は１０％以下であり、更にトリエステル以
上のエステルを含有しないのが望ましい。モノエステル
含有率が９０重量％未満のものは、乳化能は示すが可溶
化能はほとんど示さない。またその構成脂肪酸は炭素数
が１２以上２２未満のものであり、飽和，不飽和，分岐
いずれでもかまわないが、飽和脂肪酸が好ましい。The monoester of sucrose fatty acid ester used in the present invention is an ester compound of sucrose and a higher fatty acid and has a degree of esterification of 1. The monoester content is 90% or more, the diester or more ester content is 10% or less, and it is desirable that the triester or more ester is not contained. When the monoester content is less than 90% by weight, the emulsifying ability is exhibited but the solubilizing ability is hardly exhibited. The constituent fatty acid has a carbon number of 12 or more and less than 22, and may be saturated, unsaturated or branched, but saturated fatty acid is preferable.
【０００６】ビタミンＫの可溶化剤として、モノエステ
ル含有率９０％以上のショ糖脂肪酸エステルをビタミン
Ｋ１重量部に対し１〜１０重量部使用し、水に可溶化さ
せる。そして通常水溶液の形態で使用される。水との割
合は特に限定されない。また、可溶化剤として従来より
使用されているポリオキシエチレン硬化ヒマシ油やポリ
オキシエチレンソルビタン脂肪酸エステル，可溶化助剤
としてプロピレングリコールやポリエチレンオキサイ
ド，油脂等を併用することも可能である。As a solubilizing agent for vitamin K, 1 to 10 parts by weight of sucrose fatty acid ester having a monoester content of 90% or more is used with respect to 1 part by weight of vitamin K to solubilize it in water. It is usually used in the form of an aqueous solution. The ratio with water is not particularly limited. It is also possible to use polyoxyethylene hydrogenated castor oil or polyoxyethylene sorbitan fatty acid ester conventionally used as a solubilizer, and propylene glycol, polyethylene oxide, fats and oils as a solubilizing aid.
【０００７】[0007]
【作用】ショ糖脂肪酸エステルのモノエステルの特徴と
しては、（イ）ショ糖脂肪酸エステルのモノエステルは
水溶性が高い（ロ）通常市販のショ糖脂肪酸エステル
は、モノエステル，ジエステル，ポリエステルの混合物
のため乳化能は示しても可溶化能は示さないが、ショ糖
脂肪酸エステルのモノエステルは可溶化能に優れる
（ハ）ショ糖脂肪酸モノエステルはその構造中にポリオ
キシエチレン鎖を持たないため曇点がなく、水溶液の保
存条件により白濁したり、可溶化力が変化することがな
い、という点が挙げられ、これらの特徴により従来にな
いビタミンＫの可溶化が達成される。[Function] The characteristics of the monoester of sucrose fatty acid ester are (a) the monoester of sucrose fatty acid ester is highly water-soluble. (B) The commercially available sucrose fatty acid ester is a mixture of monoester, diester and polyester. Therefore, sucrose fatty acid ester monoester is excellent in solubilizing ability even though it shows emulsifying ability, but sucrose fatty acid monoester does not have polyoxyethylene chain in its structure. It has no cloud point and does not become cloudy or the solubilizing power does not change depending on the storage conditions of the aqueous solution. Due to these characteristics, unprecedented solubilization of vitamin K is achieved.
【０００８】[0008]
【実施例】次に実施例により本願発明を具体的に説明す
る。実施例，比較例の処方を表１，表２に示す。EXAMPLES Next, the present invention will be specifically described by way of examples. The formulations of Examples and Comparative Examples are shown in Tables 1 and 2.
【０００９】[0009]
【表１】 [Table 1]
【００１０】[0010]
【表２】 [Table 2]
【００１１】実施例１
ビタミンＫ1 １００ｍｇ，ショ糖モノステアレート（モ
ノエステル含有率９８．５重量％）５００ｍｇを混合
し、８０℃の水浴上で均一にしたのち、撹拌しながら８
０℃に加温した精製水５mlを加えた。さらにブドウ糖５
００ｍｇを加えたのち、精製水を加え全量を１０mlとし
た。得られた可溶化液を濾過後、褐色アンプルビンに充
てんし、窒素ガスで置換の後熔閉した。これをオートク
レーブで１ｋｇ／ｃｍ2 ，２０分間加熱して殺菌した。Example 1 Vitamin K 1 ( 100 mg) and sucrose monostearate (monoester content 98.5% by weight) (500 mg) were mixed and homogenized in a water bath at 80 ° C., and then stirred while stirring.
5 ml of purified water heated to 0 ° C was added. More glucose 5
After adding 00 mg, purified water was added to bring the total amount to 10 ml. The obtained solubilized solution was filtered, filled in a brown ampoule, replaced with nitrogen gas, and then sealed. This was sterilized by heating in an autoclave at 1 kg / cm 2 for 20 minutes.
【００１２】実施例２
ビタミンＫ1 １００ｍｇ，ショ糖モノステアレート（モ
ノエステル含有率９８．５重量％）５００ｍｇ，プロピ
レングリコール５００ｍｇを混合し、８０℃の水浴上で
均一にしたのち撹拌しながら８０℃に加温した精製水５
mlを加えた。さらにブドウ糖５００ｍｇを加えたのち、
精製水を加え全量を１０mlとした。以下実施例１と同様
に操作した。Example 2 100 mg of vitamin K 1 , 500 mg of sucrose monostearate (monoester content 98.5% by weight), and 500 mg of propylene glycol were mixed and homogenized in a water bath at 80 ° C., and then mixed with 80. Purified water heated to ℃ 5
ml was added. After adding 500 mg of glucose,
Purified water was added to bring the total volume to 10 ml. Thereafter, the same operation as in Example 1 was performed.
【００１３】実施例３
ビタミンＫ1 １００ｍｇ，ショ糖モノステアレート（モ
ノエステル含有率９８．５重量％）４００ｍｇ、ポリオ
キシエチレン硬化ヒマシ油６０（エチレンオキサイド６
０モル付加物）１００ｍｇ，プロピレングリコール５０
０ｍｇを混合し、８０℃の水浴上で均一にしたのち撹拌
しながら８０℃に加温した精製水５mlを加えた。さらに
ブドウ糖５００ｍｇを加えたのち、精製水を加え全量を
１０mlとした。以下実施例１と同様に操作した。Example 3 Vitamin K 1 100 mg, sucrose monostearate (monoester content 98.5% by weight) 400 mg, polyoxyethylene hydrogenated castor oil 60 (ethylene oxide 6
0 mol adduct) 100 mg, propylene glycol 50
0 mg was mixed and homogenized on a water bath at 80 ° C, and then 5 ml of purified water heated to 80 ° C was added with stirring. After further adding 500 mg of glucose, purified water was added to make the total amount 10 ml. Thereafter, the same operation as in Example 1 was performed.
【００１４】実施例４
ビタミンＫ1 １００ｍｇ，ショ糖モノラウレート（モノ
エステル含有率９３．０重量％）４００ｍｇ，ポリソル
ベート８０を１００ｍｇ，プロピレングリコール５００
ｍｇを混合し、８０℃の水浴上で均一にしたのち撹拌し
ながら８０℃に加温した精製水５mlを加えた。さらにブ
ドウ糖５００ｍｇを加えたのち、精製水を加え全量を１
０mlとした。以下実施例１と同様に操作した。Example 4 Vitamin K 1 100 mg, sucrose monolaurate (monoester content 93.0% by weight) 400 mg, polysorbate 80 100 mg, propylene glycol 500
5 mg was mixed and homogenized on a water bath at 80 ° C., and then 5 ml of purified water heated to 80 ° C. was added with stirring. After adding 500 mg of glucose, add purified water to bring the total amount to 1
It was set to 0 ml. Thereafter, the same operation as in Example 1 was performed.
【００１５】比較例１
実施例１のショ糖モノステアレートの代替にポリオキシ
エチレン硬化ヒマシ油６０を使用し、同様の操作を行な
った。Comparative Example 1 Polyoxyethylene hydrogenated castor oil 60 was used in place of the sucrose monostearate of Example 1, and the same operation was performed.
【００１６】比較例２
実施例１のショ糖モノステアレートの代替にポリオキシ
エチレンソルビタンモノオレート（エチレンオキサイド
６０モル付加）（別称ポリソルベート８０）を使用し、
同様の操作を行なった。Comparative Example 2 Polyoxyethylene sorbitan monooleate (addition of 60 mol of ethylene oxide) (also known as polysorbate 80) was used in place of the sucrose monostearate of Example 1,
The same operation was performed.
【００１７】比較例３
実施例２のショ糖モノステアレートの代替にポリオキシ
エチレン硬化ヒマシ油６０を使用し、同様の操作を行な
った。Comparative Example 3 Polyoxyethylene hydrogenated castor oil 60 was used in place of the sucrose monostearate of Example 2 and the same operation was performed.
【００１８】比較例４
実施例２のショ糖モノステアレートの代替にポリソルベ
ート８０を使用し、同様の操作を行なった。Comparative Example 4 Polysorbate 80 was used in place of the sucrose monostearate of Example 2 and the same operation was performed.
【００１９】比較例５
実施例１のショ糖モノステアレートの代替にショ糖ステ
アレート（モノエステル含有率７０重量％）を使用し、
同様の操作を行った。Comparative Example 5 Sucrose stearate (monoester content 70% by weight) was used in place of the sucrose monostearate of Example 1,
The same operation was performed.
【００２０】評価
実施例および比較例で調製した水溶液を２０℃で６ケ月
間保存したのち、６５０ｎｍにおける透光度を測定し
た。測定結果を表３に示す。The aqueous solutions prepared in the evaluation examples and comparative examples were stored at 20 ° C. for 6 months, and then the light transmittance at 650 nm was measured. The measurement results are shown in Table 3.
【００２１】[0021]
【表３】 [Table 3]
【００２２】[0022]
【発明の効果】表３より可溶化剤として、モノエステル
含有率９０重量％以上のショ糖脂肪酸エステルを使用し
たものは、６ケ月間の保存の後も沈殿，白濁も生じず安
定であった。As shown in Table 3, the sucrose fatty acid ester having a monoester content of 90% by weight or more was used as the solubilizer and was stable without precipitation or clouding even after storage for 6 months. .
Claims (2)
ョ糖脂肪酸エステルを含有するビタミンＫ可溶化剤。1. A vitamin K solubilizer containing sucrose fatty acid ester having a monoester content of 90% by weight or more.
ミンＫ可溶化水溶液。2. A solubilized aqueous solution of vitamin K containing the solubilizing agent according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19251091A JPH0517347A (en) | 1991-07-05 | 1991-07-05 | Vitamin k-solubilizing agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19251091A JPH0517347A (en) | 1991-07-05 | 1991-07-05 | Vitamin k-solubilizing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0517347A true JPH0517347A (en) | 1993-01-26 |
Family
ID=16292489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19251091A Pending JPH0517347A (en) | 1991-07-05 | 1991-07-05 | Vitamin k-solubilizing agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0517347A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100456992B1 (en) * | 1996-07-01 | 2005-01-27 | 미쓰비시 가가꾸 푸즈 가부시끼가이샤 | Antimicrobial |
| CN114533672A (en) * | 2022-03-03 | 2022-05-27 | 南京臣功制药股份有限公司 | Vitamin K1Nano emulsion and preparation method thereof |
-
1991
- 1991-07-05 JP JP19251091A patent/JPH0517347A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100456992B1 (en) * | 1996-07-01 | 2005-01-27 | 미쓰비시 가가꾸 푸즈 가부시끼가이샤 | Antimicrobial |
| CN114533672A (en) * | 2022-03-03 | 2022-05-27 | 南京臣功制药股份有限公司 | Vitamin K1Nano emulsion and preparation method thereof |
| CN114533672B (en) * | 2022-03-03 | 2023-12-26 | 南京臣功制药股份有限公司 | Vitamin K 1 Nanoemulsion and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1965764B1 (en) | Self-emulsifying formulations of cetp inhibitors | |
| KR870009720A (en) | Sustained Release New Pharmaceutical Formulations | |
| JP4257870B2 (en) | Avermectin-containing and milbemycin-containing preparations based on castor oil | |
| JPH0510327B2 (en) | ||
| EP0094771A2 (en) | Skin treatment compositions | |
| JPH07116020B2 (en) | Liquid crystal type external base | |
| JP2860748B2 (en) | Stable hydrocortisone butyrate-containing cream | |
| JP2939082B2 (en) | Stable vitamin A palmitate and vitamin E solubilized eye drops | |
| JPH047722B2 (en) | ||
| JPH0741422A (en) | Method for solubilizing gamma-oryzanol in water | |
| JPH0812568A (en) | Cosmetic | |
| JP2822093B2 (en) | W / O / W type emulsified cosmetic | |
| JP5068750B2 (en) | Transparent pharmaceutical aqueous microemulsion containing propofol and process for production | |
| JPH0517347A (en) | Vitamin k-solubilizing agent | |
| JPH01135715A (en) | Aqueous solution of stable fat-soluble substance | |
| US4001141A (en) | Cosmetic emulsifiers | |
| JP2001072581A (en) | Liquid emulsified composition for skin | |
| JPH11246513A (en) | Aqueous liquid agent of azulene | |
| US3170836A (en) | Injectable compositions comprising a copper-containing chelate complex compound dispersed in a stabilized oil-in-water emulsion and method of using the same | |
| JPH0725735A (en) | Gargling agent | |
| JP3313148B2 (en) | External preparation for skin | |
| JP4403783B2 (en) | Emulsifying or solubilizing agent for low alcohol beverage, emulsifying or solubilizing preparation containing the same, and low alcohol beverage | |
| JPH0717860A (en) | Liposoluble substance-containing solution agent and method for emulsifying and solubilizing liposoluble substance | |
| JP2001097858A (en) | Vitamin a derivative-containing composition | |
| JPS5832899A (en) | Oxendrone aqueous suspension |